Lodge Hill Capital LLC Has $40.27 Million Holdings in Becton, Dickinson and Company $BDX

Key Points

• Lodge Hill Capital LLC increased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 12.0%, owning 175,800 shares worth approximately $40.27 million, making it the firm's second largest investment.
• Becton, Dickinson and Company reported a quarterly revenue of $5.51 billion and earnings per share of $3.68, exceeding analysts' expectations for both metrics.
• The company announced a quarterly dividend of $1.04 per share, with an annualized dividend yield of 2.1%, set to be paid on September 30th.

Lodge Hill Capital LLC raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 12.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 175,800 shares of the medical instruments supplier's stock after acquiring an additional 18,900 shares during the period. Becton, Dickinson and Company comprises approximately 9.5% of Lodge Hill Capital LLC's investment portfolio, making the stock its 2nd largest holding. Lodge Hill Capital LLC owned 0.06% of Becton, Dickinson and Company worth $40,269,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of BDX. Northstar Financial Companies Inc. increased its position in shares of Becton, Dickinson and Company by 15.0% during the first quarter. Northstar Financial Companies Inc. now owns 1,599 shares of the medical instruments supplier's stock valued at $366,000 after acquiring an additional 209 shares during the last quarter. CreativeOne Wealth LLC increased its position in shares of Becton, Dickinson and Company by 13.8% during the 1st quarter. CreativeOne Wealth LLC now owns 2,992 shares of the medical instruments supplier's stock valued at $685,000 after purchasing an additional 362 shares during the last quarter. FORA Capital LLC bought a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth $3,458,000. Caisse DE Depot ET Placement DU Quebec purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter worth about $17,529,000. Finally, Comerica Bank grew its position in Becton, Dickinson and Company by 6.2% during the first quarter. Comerica Bank now owns 66,785 shares of the medical instruments supplier's stock valued at $15,298,000 after buying an additional 3,870 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the sale, the executive vice president owned 4,575 shares of the company's stock, valued at $783,194.25. This represents a 20.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Claire Fraser sold 863 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $192.30, for a total transaction of $165,954.90. Following the transaction, the director owned 23,143 shares in the company, valued at $4,450,398.90. The trade was a 3.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,214 shares of company stock worth $579,206 in the last quarter. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $195.50 on Thursday. The firm has a market capitalization of $56.04 billion, a P/E ratio of 35.16, a P/E/G ratio of 1.45 and a beta of 0.20. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The stock's 50-day simple moving average is $182.12 and its two-hundred day simple moving average is $194.78. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. The business had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Becton, Dickinson and Company's quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the firm posted $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 74.82%.

Analysts Set New Price Targets

Several analysts have commented on BDX shares. Wall Street Zen raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. William Blair cut shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. Citigroup lowered Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and reduced their price objective for the company from $217.00 to $185.00 in a report on Thursday, May 22nd. The Goldman Sachs Group downgraded Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price target for the company. in a research note on Friday, May 2nd. Finally, Morgan Stanley increased their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Four equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $211.44.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.